Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05785741 · ClinicalTrials.gov registry record · Phase 1

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by DualityBio.

Recruiting
Registry status
Phase 1
Development phase
1,000
Enrollment target
20
Study locations

NCT05785741: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by DualityBio.

NCT05785741 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by DualityBio. The registered enrollment target is 1,000 participants, above the 188-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (432% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05785741, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by DualityBio.

RECRUITING
Registry status
Phase 1
Development phase
1,000 participants
Enrollment target
20
Study locations

Study Summary

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

Primary Outcome

Percentage of participants in Part 1 with DLTs

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Trastuzumab
  • DRUG Osimertinib
  • DRUG DB-1310

Study Locations (20)

Florida

  • D&H Cancer Research Center LLC - Margate
  • Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando
  • BRCR global - Plantation
  • Florida Cancer Specialists - Sarasota
  • BRCR Medical Center Inc. - Tamarac

California

  • University of California, Davis Comprehensive Cancer Center - Sacramento
  • UCLA Hematology/Oncology - Santa Monica - Santa Monica

Jiangsu

  • Jiangsu Province hospital - Nanjing
  • Affiliated Hospital of Jiangnan University - Wuxi

Georgia

  • Research Site 111 - Atlanta

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • Henry Ford Health System - Detroit

Ohio

  • Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center - Cincinnati

Tennessee

  • Tennessee Oncology, PLLC - Nashville

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2023-04-10
Est. Completion 2026-08-31
Phase Phase 1
DualityBio

10 total trials

What NCT05785741 shows while recruiting

NCT05785741 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 188-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (432% higher).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Trastuzumab is the first listed.

NCT05785741 names 20 study sites across 14 states, led by Florida, California, Jiangsu.

Frequently Asked Questions

What is clinical trial NCT05785741 about?

NCT05785741 is a clinical study titled "A Study of DB-1310 in Advanced/Metastatic Solid Tumors". This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

What is the current status of trial NCT05785741?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 1,000 participants. The study started on 2023-04-10. Estimated completion is 2026-08-31.

What conditions does trial NCT05785741 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05785741?

The interventions under investigation include: Trastuzumab (DRUG), Osimertinib (DRUG), DB-1310 (DRUG).

Who is sponsoring clinical trial NCT05785741?

This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05785741 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05785741's enrollment target sits among peer trials

1,000 3rd of 189 higher than 187 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05785741

Source: ClinicalTrials.gov NCT05785741, the US trial registry maintained by the National Library of Medicine. NCT05785741 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.